TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26673577
Drug: gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1000 mg/m2 plus carboplatin area under the curve 2 mg×min/mL
Study: 20958995
Drug: Hands-on passive
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hands-on passive stretching treatment procedures directed to the talocrural joint, varying in treatment speed, during the post-acute injury period.
Study: 16968578
Drug: ALN +
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN + D (alendronate 70 mg and cholecalciferol 70 microg)
Study: 16968578
Drug: ALN (alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN (alendronate 70 mg)
Study: 9241384
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment regimen with sodium artesunate (400 mg on day 1, then 200 mg daily for 4 days, total 1200 mg)
Study: 9241384
Drug: 7-day treatment
Normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day treatment regimen with sodium artesunate (400 mg on day 1, then 200 mg daily for 6 days, total 1600 mg)
Study: 27502729
Drug: FEC →
Normalized name: Fluorouracil, Epirubicin, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC → D (epirubicin 75 mg/m², 5-fluorouracil 500 mg/m², cyclophosphamide 500 mg/m² every 2 weeks for 4 cycles, followed by docetaxel 75 mg/m² every 2 weeks for 4 cycles)
Study: 27502729
Drug: TC (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC (docetaxel 75 mg/m² and cyclophosphamide 600 mg/m² every 21 days for 6 cycles)
Study: 20814844
Drug: Prefeeding oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefeeding oral stimulation program (5-min duration)
Study: 20814844
Drug: Prefeeding oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefeeding oral stimulation program
Study: 19211712
Drug: 128 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 128 mg/d candesartan
Study: 19211712
Drug: 16 mg/d
Normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/d candesartan
Study: 10475315
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 800 microg
Study: 10475315
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 200 microg
Study: 10475315
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 2 mg
Study: 10475315
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 800 microg and Intravenous morphine 10 mg
Study: 6213382
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (ipratropium bromide + fenoterol + theophylline)
Study: 6213382
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination
Study: 19864673
Drug: Trimethoprim-sulfamethoxazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (2 mg of trimethoprim plus 10 mg of sulfamethoxazole per kilogram of body weight) for 12 months
Study: 17080491
Drug: Flexible method
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible method for extensions of fixed sample or group-sequential trials with t-distributed test statistics
Study: 12743236
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 400 mg/d
Study: 12743236
Drug: Valproate (VPA)
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate (VPA) 2,250 mg/d
Study: 1487624
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg)
Study: 24424707
Drug: Vortioxetine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 2.5 mg
Study: 18621986
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg (Group K)
Study: 18621986
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg + Midazolam 37.5 microg kg(‐1) (Group KM)
Study: 16098435
Drug: Tadalafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (100 mg by mouth)
Study: 16098435
Drug: Ibutilide (0.002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (0.002 mg/kg intravenously)
Study: 28056945
Drug: Locally produced
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally produced lipid-based nutrient supplement (Wawamum) for children 6-23 months, micronutrient powders for children 24-59 months, and wheat soya blends for pregnant and lactating mothers.
Study: 24121757
Drug: TMC310911 (75‐2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC310911 (75‐2000 mg)
Study: 24121757
Drug: TMC310911 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC310911 (300 mg bid, 600 mg once daily, 150 mg bid plus 100 mg ritonavir bid, 900 mg bid alone, 300 mg bid plus ritonavir 50 mg bid)
Study: 24121757
Drug: TMC310911 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC310911 (1200 mg single-dose)
Study: 24121757
Drug: TMC310911 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC310911 (up to 2000 mg) and multiple-dose (up to 900 mg)
Study: 7859961
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen (2 L/minute) via nasal cannula
Study: 31942744
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block (0.5 mL/kg bupivacaine 0.25% every eight hours)
Study: 31942744
Drug: Paracetamol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (15 mg/kg intravenously every eight hours)
Study: 30884335
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy for 10 days
Study: 28299294
Drug: Chamomile cream
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile cream (0.5 g applied twice a day for 10 days)
Study: 28299294
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (applied twice a day for 10 days)
Study: 21327805
Drug: Dexmedetomidine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2.5 μg/kg
Study: 16896874
Drug: Microcurrent skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent skin patch (MCT) plus tramadol hydrochloride
Study: 16388069
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day ethyl-EPA
Study: 16388069
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day ethyl-EPA
Study: 1768820
Drug: Sodium thiopental
Normalized name: Thiopental Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium thiopental (3 mg/kg)
Study: 6803909
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses (regimen I)
Study: 6803909
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high doses (regimen II)
Study: 21086591
Drug: Magnetolaser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetolaser therapy in combination with whole body iodine‐bromide‐sodium chlorine baths, physical exercises, and massage
Study: 19014552
Drug: Education program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education program (structured dialogue conveying information about pathophysiology, pharmacological and non‐pharmacological treatment of GERD, patients' rights and use of healthcare)
Study: 11842293
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy for 3 years
Study: 1723461
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg once daily for 4 months)
Study: 1723461
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg once daily for 4 months)
Study: 25801231
Drug: Pseudomonas aeruginosa
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas aeruginosa preparation (PAP)
Study: 18042619
Drug: Preventive pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive pacing with four therapies
Study: 15058255
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CABG and TMLR (CABG/TMLR group)
Study: 10736287
Drug: Intravenous T(3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous T(3) at 0.4 microg/kg
Study: 10736287
Drug: Intravenous T(3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous T(3) at 0.6 microg/kg
Study: 10736287
Drug: Intravenous T(3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous T(3) at 0.8 microg/kg
Study: 8725414
Drug: Hypothermic CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic CPB (rectal temperature 27 to 28 degrees C)
Study: 8725414
Drug: Normothermic CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic CPB (rectal temperature > 36 degrees C)
Study: 28923492
Drug: ECA/Kardia intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECA/Kardia intervention (smartphone-based Embodied Conversational Agent and Alive Cor Kardia Mobile heart rhythm monitor)
Study: 20711135
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day of alpha lipoic acid for two months
Study: 20711135
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of gabapentin for two months
Study: 20711135
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 600 mg/day of alpha lipoic acid and 300 mg/day of gabapentin for two months
Study: 20711135
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of cellulose starch for two months
Study: 19907100
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg/day for 12 months
Study: 11557159
Drug: Ketamine (0.1‐0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.1‐0.5 mg/kg)
Study: 9500318
Drug: sublingual/oral immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual/oral immunotherapy
Study: 8719303
Drug: Repeated hexarelin
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated hexarelin administration
Study: 2703387
Drug: Misonidazole (MISO)
Normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole (MISO) 1 g/m2/d with brachytherapy for ENT tumors
Study: 2703387
Drug: Misonidazole (MISO)
Normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole (MISO) 1 g/m2/d with hypofractionated external radiotherapy for breast cancer
Study: 2703387
Drug: Misonidazole (MISO)
Normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole (MISO) 1 g/m2/d with hypofractionated external radiotherapy for large ENT tumors
Study: 329375
Drug: Secretolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secretolytic agents
Study: 31971034
Drug: Antipsoriatic drugs
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antipsoriatic drugs (10 drugs including 3 oral medications and 7 biologic agents)
Study: 31971034
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of treatment alone
Study: 22070722
Drug: Physiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy with respiratory therapy and 'hot roll' treatment on radiation treatment days.
Study: 16278069
Drug: Aceclofenac administered
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac administered preoperatively (2 tablets of 100 mg taken orally 1h before surgery)
Study: 16278069
Drug: Aceclofenac administered
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac administered postoperatively (2 tablets of 100 mg taken orally in the early postoperative period)
Study: 8961972
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy beyond 5 years
Study: 8961972
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy for estrogen receptor-positive tumors
Study: 1842806
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral quinine (1050 mg in two divided doses daily for five days)
Study: 7129168
Drug: Problem-solving training
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving training (practical solutions for everyday difficulties)
Study: 3907823
Drug: Bromocriptine, 18-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine, 18-150 mg/day (mean, 72.5)
Study: 27283947
Drug: Vinpocetine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine 30 mg intravenously once daily for 7 days
Study: 27283947
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (cytidine disphosphate choline + aspirin/clopidogrel)
Study: 22652556
Drug: Calcifediol (Hidroferol®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcifediol (Hidroferol®, 1 ampoule: 266 μg) administered weekly after HD for 6 doses
Study: 18818572
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + cilostazol
Study: 15879923
Drug: 0.05 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/day vaginal ring
Study: 15879923
Drug: 0.1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/day vaginal ring
Study: 15879923
Drug: 0.0075 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0075 mg/day vaginal ring (active comparator)
Study: 8759656
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg qAM
Study: 8759656
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg qPM
Study: 8759656
Drug: All regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: All regimens of omeprazole 40 mg
Study: 6759285
Drug: Verapamil 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 480 mg daily
Study: 6759285
Drug: Nifedipine 60
Normalized name: nifedipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 60 mg daily
Study: 31285414
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of Tranexamic Acid (TXA) 1.5 g in 50 ml normal saline
Study: 11994058
Drug: Chlorpheniramine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine alone (8 mg)
Study: 11994058
Drug: Chlorpheniramine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine with quinidine (50 mg every 6 h for 2 days prior and during the study)
Study: 10654755
Drug: Aminophylline cream
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline cream applied twice daily to one thigh/buttock (placebo on the other)
Study: 10654755
Drug: Endermologie treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endermologie treatment applied twice weekly to one thigh/buttock
Study: 10654755
Drug: Endermologie treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endermologie treatment applied to both thighs/buttocks with the same cream regimen as group 1
Study: 9121998
Drug: Before treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before treatment (I)
Study: 9121998
Drug: On the
Normalized name: Meds on the Go KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the 3rd treatment week (II)
Study: 1929772
Drug: Clomipramine hydrochloride
Normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine hydrochloride (mean dose 120 +/- 48 mg/d)
Study: 1929772
Drug: Desipramine hydrochloride
Normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine hydrochloride (mean dose 135 +/- 53 mg/d)
Study: 22676430
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) provided by MSWs in clients' homes
Study: 12149503
Drug: Cetirizine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (0.25 mg/kg twice a day over 18 months)
Study: 7650070
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 50 mg flurbiprofen
Study: 7650070
Drug: Single topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single topical application of a 40 mg flurbiprofen patch
Study: 7650070
Drug: Repeated application
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated application of the topical patch (twice daily for 7 days)
Study: 7650070
Drug: Topical patch
Normalized name: Mega Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical patch
Study: 2745390
Drug: Fenfluramine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine 1.5 mg/kg daily for 3 months
Study: 31047901
Drug: Data-driven cluster
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data-driven cluster analysis for selecting glucose-lowering therapy
Study: 23768260
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus exposure therapy
Study: 19157318
Drug: Methadone (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (20-60 mg daily, tapered over 2 weeks)
Study: 19157318
Drug: Methadone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone + TENS (10-30 mg daily, tapered over 2 weeks with TENS treatment)
Study: 7930339
Drug: Methylprednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (10 mg intravenous dose)
Study: 3168338
Drug: Ionic amidotrizoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic amidotrizoate (370 mg/ml, osmolality 2.1 osmol/kg)
Study: 3168338
Drug: Nonionic iopamidol
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonionic iopamidol (370 mg/ml, osmolality 0.8 osmol/kg)
Study: 20002085
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg voriconazole orally
Study: 20002085
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg voriconazole intravenously
Study: 11707792
Drug: Intradermal needles
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal needles inserted into painful points
Study: 11707792
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (needles inserted into nonpainful points)
Study: 15374366
Drug: Idebenone (CV-2619)
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Idebenone (CV-2619) 90 mg/daily
Study: 6376128
Drug: High-dose cis-platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cis-platinum (100 mg/m2) + adriamycin (60 mg/m2)
Study: 6376128
Drug: Adriamycin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (60 mg/m2) + cis-platinum (60 mg/m2)
Study: 26401858
Drug: Local levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local levobupivacaine infiltration (20 mL of levobupivacaine 0.25%)
Study: 26401858
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1g before extubation and 5g in the 24 postoperative period)
Study: 26401858
Drug: Intravenous lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lornoxicam (8 mg before extubation and 8 mg in the 24 postoperative period)
Study: 17404779
Drug: Melatonin (3mg)
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (3mg) administered one hour before bedtime for four weeks
Study: 17404779
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered one hour before bedtime for four weeks
Study: 11498721
Drug: Oral cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cocaine (62.5, 125, 250 mg/70 kg)
Study: 11498721
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (12.5, 25, 50 mg/70 kg)
Study: 11498721
Drug: Oral cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cocaine
Study: 11498721
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine
Study: 11498721
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and intravenous cocaine
Study: 9919334
Drug: CPT-11 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (irinotecan hydrochloride) at a dose of 120 mg/m2 i.v. over 4 hours on days 1 and 15, and mitomycin-C (MMC) at a dose of 7 mg/m2 i.v. as a bolus on days 1 and 15, given for at least 2 cycles, 4 weeks apart.